An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants
Clinical trial NCT00528528 · COMPLETED
Trial details
- NCT number
- NCT00528528
- Sponsor
- Tibotec BVBA
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-10-01
- Primary completion
- 2009-07-01
- Enrollment
- 166
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.